TOP NEWS: GlaxoSmithKline rejects three Unilever bids for Consumer arm

(Alliance News) - GlaxoSmithKline PLC on Saturday confirmed it has received and rejected three ...

Alliance News 17 January, 2022 | 6:38AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - GlaxoSmithKline PLC on Saturday confirmed it has received and rejected three unsolicited and non-binding bids for its Consumer Healthcare business from consumer goods maker Unilever PLC.

The latest offer from Unilever was made on December 20 and had a total acquisition value of GBP50 billion, comprising GBP41.7 billion in cash and GBP8.3 billion in Unilever shares.

The offer was rejected by the Brentford, England-based pharmaceutical group, on the grounds that the offer undervalued the business. The approach was first reported by the Sunday Times newspaper on Saturday.

"The board of GSK unanimously concluded that the proposals were not in the best interests of GSK shareholders as they fundamentally undervalued the Consumer Healthcare business and its future prospects," Glaxo said.

GSK said it remains focused on carrying on with the proposed demerger of its Consumer Healthcare arm, and having it list on the London Stock Exchange in mid-2022.

The business was formed in August 2019 as a joint venture with Pfizer Inc, which holds a 32% interest, while GSK holds the remaining 68%.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Unilever PLC 4,070.00 GBX 5.36
GlaxoSmithKline PLC 1,647.59 GBX 0.71
Pfizer Inc 26.27 USD -0.19

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures